Carcinoma, Intraductal, Noninfiltrating clinical trials at UCSF
1 in progress, 1 open to new patients
open to eligible females ages 18 years and up
This is a pilot study to investigate the change in the immune microenvironment of high risk ductal carcinoma in situ (DCIS) after short term exposure to pembrolizumab.
San Francisco, California